Clinical Trials Sponsored by Saisei Pharma

Total 10193 results

Saisei Pharma

Completed

Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR)

Covid19

Ukraine
Asahi Kasei Pharma Corporation

Recruiting

Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Asahi Kasei Pharma Corporation

Completed

Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer

Postoperative Stage II/III Colon Cancer

Japan
Asahi Kasei Pharma Corporation

Completed

Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study

Diabetes

United States
Asahi Kasei Pharma Corporation

Completed

Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Japan
Asahi Kasei Pharma Corporation

Completed

Clinical Study of AK159 in Healthy Postmenopausal Women

Osteoporosis

Japan
Asahi Kasei Pharma Corporation

Completed

Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

Deep Mycosis

Japan
Asahi Kasei Pharma Corporation

Completed

Collagenase Option for Reduction of Dupuytren's Contracture in Japan (CORD-J)

Dupuytren's Contracture

Japan
Asahi Kasei Pharma Corporation

Completed

A Phase I Study of AK159 in Healthy Postmenopausal Women

Osteoporosis

Japan
Asahi Kasei Pharma Corporation

Completed

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Poland, Ukraine, Germany, Hungary, United Kingdom, Slovakia, Czech Republic
Asahi Kasei Pharma Corporation

Completed

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Germany, Romania, Hungary, Lithuania, Czech Republic, United Kingdom
Asahi Kasei Pharma Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis

Lupus Nephritis

China
Asahi Kasei Pharma Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome

Nephrotic Syndrome

China
Asahi Kasei Pharma Corporation

Completed

Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment

Disseminated Intravascular Coagulation

Japan
Asahi Kasei Pharma Corporation

Completed

Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke

Severe Upper Limb Hemiplegia

Japan
Asahi Kasei Pharma Corporation

Completed

Study of AK156 in Primary Osteoporosis Patients

Osteoporosis

Japan
Asahi Kasei Pharma America Corporation

Completed

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Severe Sepsis | Coagulopathy

Korea, Republic of, United States, Taiwan, Netherlands, United Kingdom, Australia, Canada, Belgium, Israel, Spain, New Zealand, France, Brazil, India, Argentina, Bulgaria, Croatia, Czechia, Finland, Germany, Hungary, Peru, Russian Federation and more
Asahi Kasei Pharma America Corporation

Withdrawn

The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy (Scarlet2)

Sepsis and Coagulopathy
R-Pharm
Covance; Cromos Pharma LLC

Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

COVID-19
Sinew Pharma Inc.
Taipei Veterans General Hospital, Taiwan

Recruiting

To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose

Hepatitis

Taiwan
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Rheumatoid Arthritis

United States, Belgium, United Kingdom
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
Yuria-Pharm
Pharmaxi LLC

Completed

Epidemiological Study of the COVID-2019 in Participating Organizations.

Covid19

Ukraine
Asahi Kasei Pharma Corporation
Emergent Clinical Consulting, LLC

Terminated

First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) (ENHANCE)

Spinal Stenosis | Degenerative Spondylolisthesis

Canada
Taipei Medical University
Taiwan Otsuka Pharm. Co., Ltd

Active, not recruiting

Effect of HINEX Jelly on Nutritional Status in People With Possible Sarcopenia or Sarcopenia

Sarcopenia

Taiwan
PT Sydna Farma
PT Pharma Metric Labs

Completed

Bioequivalence Study of Cyproterone Acetate and Ethinyl Estradiol in Healthy Female Volunteers

Drug Use

Indonesia
Monash University
Caring Pharmacy; Bionime Corporation; Tigas Pharma

Active, not recruiting

Prevention and Treatment of Diabetes in Adults

PreDiabetes

Malaysia
UCB Biopharma S.P.R.L.
Pharm Research Associates (UK) Ltd.

Completed

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (BASE)

Epilepsy With POS With or Without Secondary Generalization

Denmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
UCB Pharma SA

Completed

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Epilepsy

United States, Belgium, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
UCB Pharma SA

Completed

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

Epilepsy, Partial

Canada, United States
Vifor Pharma, Inc.

Terminated

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)

Hyperkalemia

United States, Bulgaria, Canada, Georgia, Germany, Poland, Ukraine
UCB Pharma SA

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Belgium, Finland, France, Germany, Hungary, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
UCB Pharma SA

Completed

Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy

Generalized Epilepsy
UCB Pharma SA

Completed

Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)

Dermatitis, Atopic
UCB Pharma SA

Completed

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (PRECiSE 3)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
NicOx
Theradis pharma; Iris Pharma

Withdrawn

Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240) (Goldeneye)

Adenoviral Conjunctivitis

Spain
UCB Pharma GmbH

Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy (VICTOS)

Focal Epilepsy With and Without Secondary Generalization

Germany, Austria
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults

Unverricht-Lundborg Disease

France, Italy, Sweden, Finland, Netherlands, Tunisia, Réunion
UCB Pharma SA

Completed

Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects

Healthy Volunteers

United Kingdom
UCB Pharma SA

Terminated

Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease (REFRESH-PD)

Advanced Idiopathic Parkinson's Disease

United Kingdom
Astellas Pharma Inc
Advanz Pharma

Completed

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

Atrial Fibrillation | Atrial Flutter

United States, Argentina, Canada, Chile, Denmark, Mexico, Sweden
PT. Pyridam Farma Tbk
PT Pharma Metric Labs

Completed

Bioequivalence Study of Metformin Hydrochloride 500 mg Film-Coated Tablets in Indonesia Healthy Subject

Drug Use

Indonesia
Laboratories Leon Farma, S.A.
Chemo France

Completed

Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Contraception

United States
UCB Pharma SA

Completed

Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes

Narcolepsy With Cataplexy

Belgium
UCB Pharma SA

Completed

A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects

Healthy Volunteers

Netherlands
UCB Pharma SA

Completed

Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)

Epilepsy

United States, France, Germany, Spain, United Kingdom
UCB Pharma GmbH

Completed

Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease (NEUPAD)

Idiopathic Parkinson's Disease

Germany, Austria
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy

Epilepsy

Ukraine, Belgium, Germany, Hong Kong, India, South Africa, Taiwan, Sweden, Korea, Republic of, Singapore, Russian Federation, Austria, Italy, Norway, Czechia
UCB Pharma GmbH

Completed

Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug (VITOBA)

Epilepsies, Partial

Germany

Clinical Trials Sponsored by Saisei Pharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations